Kornimate/medical-research-clean huggingface dataset:
a weight-neutral approach for a healthier lifestyle among obesity - a lifestyle intervention anchored in sdoi

Conditions: Health Related Quality of Life and Weight Condition

Summary: the study aim is to evaluate a patient-centred intervention focusing on improved quality of life and wellbeing among individuals with obesity and risk factors for adverse outcome.

in denmark, university hospital of southern denmark in esbjerg has initiated the south danish obesity initiative (sdoi) to optimize the treatment of and the research in obesity. the hospital has for years, offered treatment to individuals with obesity, however, sdoi is an investigation program with the aim to identify people with undiagnosed obesity-related diseases by a systematic and stepwise approach, delivering an up-to-date treatment of diagnosed diseases and offering personalized lifestyle advice based on the finding in the investigation program. the sdoi program comprises collaboration between different medical departments at the hospital and furthermore, entails the establishment of a well-defined cohort as a basis for research. act is of interest in the construction of the personalized lifestyle advice in the sdoi program. however, there is limited research available on the effect of the behaviour therapy act as a basic method for a lifestyle program targeting overweight individuals who have been made aware of obesity related diseases and re-conditions. act might be a valuable tool to assist these individuals to increase their quality of life and thereby, ability to make lifestyle changes.

Eligibility criteria:
inclusion criteria: * participants will be eligible for inclusion if they are ≥18 years * body mass index above 30 kg/m2 exclusion criteria: * individuals referred for bariatric surgery will not be eligible for inclusion in the study
bone tissue engineering with dental pulp stem cells for alveolar cleft repair

Conditions: Cleft Lip and Palate

Summary: iliac crest autogenous bone graft is accepted as the most effective method for secondary alveolar cleft repair. however this method is associated with complications. as an alternative, mesenchymal stem cells associated with biomaterials have been used for the rehabilitation of the alveolar bone cleft of patients with cleft lip and palate. this is a rct comparing mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials versus iliac crest autogenous bone graft for secondary alveolar cleft repair.


Eligibility criteria:
inclusion criteria: * non syndromic unilateral cleft lip and palate; * age between 7 and 12 years; * to have the jaw aligned and ready to receive the graft. exclusion criteria: * previous surgery to correct the alveolar cleft; * have the canine erupted before grafting; * incomplete orthodontic treatment; * incomplete ct scan documentation.
efficacy and safety of light therapy in the treatment of non-seasonal depressive disorder in chinese population

Conditions: Major Depressive Disorder

Summary: depression is a kind of mental illness with high incidence, high recurrence and high disability. but so far, treatment remission rates for depression remain low. therefore, it is necessary to develop more new treatments. light therapy has been shown to be effective in treating depression with seasonal patterns. although most studies have reported that light therapy is also effective in patients with depression without seasonal patterns, high-quality clinical studies are still rare and the conclusions are still controversial. in particular, it remains unclear whether light therapy is effective in treating depression without seasonal patterns in the chinese population. in addition, there is a lack of biomarkers that predict the efficacy of light therapy. in conclusion, this study intends to conduct an add-on randomized controlled study to clarify the efficacy and safety of light therapy as synergistic therapy in patients with depression without seasonal patterns, and to screen peripheral biomarkers related to efficacy using transcriptome sequencing technology. it is expected that this study can confirm the effectiveness and safety of light therapy as synergistic therapy, provide an evidence-based basis for the research and exploration of light therapy in chinese depression population, and provide more options for the synergistic treatment of antidepressants in chinese depression population.


Eligibility criteria:
inclusion criteria: 1）meets dsm-5 criteria for major depressive disorder 2) age 18-65; 3) hamd-17 score ≥17; 4) no antidepressants or mood stabilizers were used at least 2 weeks before enrollment; 5) sign informed consent. exclusion criteria: 1. with seasonal pattern; 2. no previous mental disorders, personality disorders, mental retardation, neurodegenerative diseases, brain trauma, cerebrovascular diseases caused by organic diseases; 3. no previous history of alcohol or substance dependence; 4. current serious risk of suicide (e.g., previous attempted suicide or recent suicidal behavior); 5）present with serious, active physical diseases that may interfere with research, including vision problems and photosensitivity disorders; 6）have received electroconvulsive therapy (ect or mect) or transcranial magnetic stimulation (rtms) in the last 6 months.
probiotics/tpn in the nicu

Conditions: Total Parenteral Nutrition; Necrotizing Enterocolitis of Newborn

Summary: the purpose of this study is to evaluate the effect of probiotic administration on tpn dependence in infants \< 32 weeks ga and bw 1500 grams or less in the banner - university medical center phoenix and banner children's at desert neonatal intensive care units (nicu). the primary endpoint of capturing the number of days of tpn administration can reflect that an infant is progressing towards readiness for the initiation or advancement of enteral feedings at an earlier interval. the relationship between probiotic administration and the incidence of nec, culture positive sepsis, and mortality is of interest to us and will be captured. finally, the assessment of the tolerance of probiotic administration and the potential positive impact on growth and development in these premature infants may validate our current practices.


Eligibility criteria:
inclusion criteria: * birth weight \< 1500 grams or ga \< 32 weeks exclusion criteria: * life threatening congenital anomalies * transfers to another facility prior to discharge home * investigator discretion to exclude if deemed necessary
prostic registry of men treated with psma theranostics

Conditions: Prostate Cancer; Metastatic Castration-resistant Prostate Cancer

Summary: this is a descriptive, observational, prospective, open-ended, registry utilising electronic data capture to collect information on the outcomes of men treated with prostate specific-membrane antigen (psma) theranostics.

the aim of the registry is to collect data of men with pre-treated metastatic castration-resistant prostate cancer (mcrpc) receiving lutetium 177 (177lu)-psma outside of a clinical trial to assess "real world" anti-tumour utility. the primary objective is to assess prostate specific antigen (psa) response rate to 177lu-psma in men with mcrpc. patients with mcrpc who have have progression or intolerance on a novel anti-androgen targeted agent (abiraterone and/or enzalutamide and/or apalutamide) will be eligible for the study. the investigators intend to evaluate the safety of 177lu-psma, in addition to determining patient psa progression-free survival (pfs), objective radiographic response rates and overall survival (os). health-related quality of life (qol) and pain will also be observed. additional objectives are to identify biomarkers and assess the relationship between psma and f-fluorodeoxyglucose (fdg) positron emission tomography-computed tomography (pet/ct) parameters associated with clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mcrpc 2. progression or intolerance on a novel anti-androgen therapy (e.g. abiraterone, enzalutamide, apalutamide or darolutamide) 3. prior therapy with at least one taxane cytotoxic (these agents may have been received upfront for metastatic hormone-sensitive prostate cancer) or the patient is symptomatic and assessed as unfit for chemotherapy 4. referred to nuclear medicine and being considered for lu-psma therapy according to institutional procedure guidelines

Keywords: prostate cancer metastatic castration-resistant prostate cancer theranostic 177lu-psma radionuclide therapy
passive thoughts in functional movement disorders

Conditions: Functional Movement Disorder

Summary: passive thoughts also known as mind-wandering are the thoughts that are not produced from the current task. when we aren't focused on a task that needs our full attention, our minds tend to drift from one thought to another. it is believed that mind wandering is the baseline or natural state of the mind, and we shift our focus only when needed for a task. many areas of the brain are active during mind-wandering, and these areas together are called the brain's default network. an important part of this network is the right temporoparietal junction. functional movement disorder (fmd) is characterized by unusual movements or walking difficulties that are not caused by a specific brain or nerve injury. functional movement disorders are believed to be caused due to loss of sense of agency. the sense of agency is the awareness that one is responsible for their own actions. the brain network involved in the sense of agency is mainly located in the right side of the brain, especially in the right temporoparietal junction. in fmd patients, there is decreased connectivity between the right temporoparietal junction and other brain areas that control movement. since both passive thoughts (mind wandering) and the sense of agency involve the temporoparietal junction, and because the sense of agency is abnormal in functional movement disorders (fmd), we plan to study passive thoughts in individuals with fmd. the study aims to find out how passive thoughts differ between individuals with fmd and healthy individuals. passive thoughts will be measured using mind excessively wandering scale (mews).

to evaluate passive thoughts in functional movement disorders (fmd), we will collect data from 30 fmd patients and 30 healthy controls. patients will be recruited from the movement disorders clinic and the integrated functional movement disorders clinic at lhsc. both groups will be asked to complete the paper-based mind excessively wandering scale (mews) to evaluate passive thoughts. additionally, fmd patients will complete the world health organization disability assessment schedule 2.0 (whodas 2.0), a 36-item self-administered questionnaire designed to measure disability over the past 30 days. completing both questionnaires will take approximately 15-20 minutes. the questionnaires will be completed once.

Eligibility criteria:
inclusion criteria for cases: 1. diagnosed with a functional movement disorder by the neurologist. 2. able to understand and read english. exclusion criteria for cases: 1. unable to understand and read english. 2. diagnosed with dementia.
identification of β cell dysfunction in relatives of individuals with type 1 diabetes mellitus

Conditions: Type 1 Diabetes

Summary: despite the valuable information derived from older studies evaluating type 1 diabetes, the diabetes research community has, in large part, overlooked potential contributions of baseline abnormalities in β cell function to t1d development. newer studies focusing on higher risk individuals often exclude family members without evidence of positive islet autoantibodies. new technologies to assay alternative biomarkers of β cell stress and death remain incompletely explored in both ab negative and ab positive family members of t1d patients. specifically, modern biomarkers of β cell dysfunction have not been rigorously tested in combination with metabolic testing to fully understand their association with insulin secretion. the investigator's working hypothesis is that individuals at genetic risk for t1d exhibit baseline β cell dysfunction, even before development of detectable islet autoimmunity (seropositivity for islet abs).


Eligibility criteria:
inclusion criteria for each subject group\* note age limits different for each group\*: * nonrelative controls: male and female adults 18-55 years old with no family history of type 1 diabetes, who have tested negative for glutamic acid decarboxylase, microinsulin, islet cell, islet antigen 2, and zinc transporter 8 autoantibodies * ab negative fdrs: male and female adults 18-50 years old with a first degree relative (sibling, child, or parent) with t1d, who have tested negative for the above islet autoantibodies * ab + t1d relatives: male and females aged 12-50 years old with a first or second degree relative diagnosed with t1d, and testing positive for 1 of the above islet autoantibodies either at the screening visit, or through trialnet screening obtained within the past 12 months. criteria for all subjects: * bmi≤40 kg/m2 (if fdr is 40 kg/m2, the healthy control bmi can not exceed 45 kg/m2) * hba1c\< 5.7% * no medical history of diabetes. exclusion criteria for all participants: * any type of diabetes or hyperglycemia (hba1c≥5.7%) * chronic illness or use of medications which interfere with glucose or islet hormone metabolism. * hemoglobin \< 12 g/dl * presence of any psychiatric disorder that will affect the ability to participate in the study * pregnancy * severe milk or soy allergy that would disallow boost® ingestion for mmtt * any condition that, in the judgment of the investigator, will adversely affect adequate participation in, or the safety or technical performance of the protocol.
functional impact of interval training on muscle mass and strength in obese adults

Conditions: Obese; Muscle Strength; Interval Training

Summary: the primary objective was to investigate the effectiveness of interval training and to evaluate the best available method for measuring body composition and functional capacity. thirty obese subjects consecutively voluntarily participated in the current study. they ranked sedentary according to their level of activity (≥ 30-minute moderate physical activity 3days/wk). the training sessions were divided into the warm-up phase, training phase and a cool-down phase. the training programs were completed 3days/week for 12 weeks. body composition was calculated by skinfold thickness method and bio-impedance before and after training. similarly, aerobic capacities were measured by lactate threshold testing and by astrand submaximal testing.


Eligibility criteria:
inclusion criteria: * 30 obese (bmi ≥ 30) and * sedentary lifestyle subjects (sample size was calculated by using who sample size calculator) * age 30-45 years and * hypercholesteremia exclusion criteria: * hypertension, * diabetes, * cardiovascular diseases * systemic diseases

Keywords: obesity body composition exercise testing
effect of erugliflozin on liver fat, liver fibrosis and glycemic control in type ii dm patients with nash/nafld

Conditions: Liver Fat; Liver Fibrosis; Glycemic Control; Body Weight Changes; Waist Circumference; Tolerance

Summary: open-label, prospective, single-arm, multicenter study to determine effects of ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash)


Eligibility criteria:
inclusion criteria: * patient able to provide written informed consent * adult males \& females between 18 to 65 years * sglt2i and insulin naïve patients * bmi \>23 kg/m2 * hba1c % ≥ 6.5 to 10 * documented hepatic steatosis or fatty liver disease on ultrasound * patient with type ii diabetes mellitus exclusion criteria: * history of use of sglt 2 inhibitors or glucagon-like peptide (glp) 1 agonist or insulin; 3 months prior to enrollment in the study. * pioglitazone use in the past 6 months * history of vitamin e use (400mg twice daily) 3 months prior to enrollment in the study. * history of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study. * history of uncontrolled endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or cushing's syndrome) * history of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and/or hiv * history of recurrent utis and mycotic infection. * severely ill patients (who have high grade fever, sepsis or acute infection) * pregnant woman, lactating woman or planning pregnancy during study duration * history of drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines). * history of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and/or laboratory tests * alcohol intake 10 - 30 g/day (three drinks per day) within the previous year * active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines. * severe hepatic impairment ( ast \& alt levels \> 3 times upper limit normal
important data on covid-19 profile in africa

Conditions: Coronavirus Infection; Africa

Summary: the purpose of this study is to understand the natural history of coronavirus 2019 (covid-19) infection to better define the period of infectiousness and transmissibility and to establish biobanks of covid-19 blood and mucosal samples.

in this study ,the participants will be enrolled sequentially in the covid-19 care referral centers. the infected hospitalized patient will be identified by the physicians in hospital. after the patient has given his/her informed consent the permission will be sought from him to approach his household contacts. the household contacts will be screened, and included in the study. patients hospitalized and positive for covid-19 by pcr and their household contacts of all ages and gender (40% minimum of female), will be enrolled upon receipt of written informed consent.

Eligibility criteria:
inclusion criteria: * molecular (pcr) confirmed covid-19 patients hospitalized in referral centers, * household contacts of hospitalized covid-19 patient, * provided signed informed consent. exclusion criteria: * pregnancy

Keywords: coronavirus infection sars-cov covid-19 transmission africa
hincab-study. home based intervention in nursing for coronary artery bypass patients

Conditions: Anxiety; Depression

Summary: hincab-study is a single senter, prospective, randomised controlled trial. the aim of the study is to test the effect of a home based intervention program. the hypothesis of the study is that a home based intervention will influencing coping strategies in the cabg-patients rehabilitation phase, reduce symptoms and improve health related quality of life.

research has shown better quality of life for patients after cabg. at the same point of time studies shows that patients experience anxiety and depression years after surgery. anxiety and depression appear frequently at the same time and strengthen each other. studies underline that cabg-patients especially the first month after surgery want follow-up by health care provider. anxiety and depression are assessed as independent risk factors for morbidity and death in heart patients. 203 cabg-patients were randomised into the study. both patient group, the experimental- and control group, answered the same three standardised questionnaires before surgery, 6 weeks and 6 months after surgery. the questionnaires are hospital anxiety and depression scale (hads), seattle angina questionnaire (saq) and sf-36. the intervention consist of two home visits 2 and 4 weeks after cabg undertaken by project leader. the intervention protocol has been approved by the norwegian committee for medical research ethics. knowledge from this study may generate a basis for clinical guidelines and patient pathways. results from this study will show if the home based intervention in the future will be performed for only a risk group of about 20 % that have responded best to the intervention. in the future the intervention also may be individualized electronically.

Eligibility criteria:
inclusion criteria: elective cabg-patients admitted to ullevål university hospital. the patients must be capable, physical and mental to fill in all questionnaires. in addition, to be capable to read and understand norwegian. driving distance maximum three hours each way. exclusion criteria: patients with combined surgery (coronary- and valve replacement surgery). emergency surgery. redo. patients that related to surgery experience cerebral insult, mediastinitis or become intensive care patients will be excluded from this study.

Keywords: anxiety. depression. hrqol. psycho-educative intervention
the effect of energy drink consumption on alcohol-substance use and it's relationship with impulsivity in university students

Conditions: Energy Drinks; Alcohol Drinking; Substance Use; University Students

Summary: the objective of this study is to investigate the prevalence of energy drink, alcohol and substance use among university students; to explore whether there is a relationship between energy drink consumption and alcohol-substance use in university students or not and to evaluate effect of impulsiveness and sensation seeking on this relationship.


Eligibility criteria:
inclusion criteria: * to be university student * to be ≥ 18 years old exclusion criteria: * not willing to participate the study

Keywords: energy drinks alcohol drinking substance use
chir therapy for elderly dlbcl intolerant to chemo

Conditions: Diffuse Large B-Cell Lymphoma

Summary: the objective of exploring the application of chir is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large b-cell lymphoma (dlbcl) aged 70 and above, and to investigate the genetic subtypes that may benefit from chir. the primary endpoint is the complete remission rate (crr) at the end of 8 cycles.


Eligibility criteria:
inclusion criteria： 1. age ≥ 70 years; 2. ecog score of 0-3; 3. rated as unfit or frail on the simplified geriatric assessment (sga); 4. histologically confirmed cd20-positive diffuse large b-cell lymphoma (diagnostic criteria according to who 2016), excluding transformed type 2 dlbcl; 5. immunohistochemically confirmed positive expression of myc and bcl2 (myc ≥ 40%, bcl2 ≥ 50% by immunohistochemistry); 6. previously untreated patients; 7. cardiac, hepatic, and renal function: creatinine \< 2 times the upper limit of normal (uln); alt (alanine aminotransferase)/ast (aspartate aminotransferase) \< 2.5 uln; total bilirubin \< 2 uln; 8. at least one measurable lesion; 9. unable to tolerate standard chop regimen chemotherapy or unwilling to receive chemotherapy; 10. adequate understanding and voluntary signing of the informed consent form. exclusion criteria： 1.patients with central nervous system involvement at the time of onset; 2.known human immunodeficiency virus (hiv) infection; 3.pregnant or lactating women; 4.other tumors requiring treatment; 5.uncontrollable active infection; 6.active hepatitis with hbv-dna copy number not controlled within 2\*1000/ml despite antiviral treatment; 7.inability to understand, comply with the study protocol, or sign the informed consent form.

Keywords: diffuse large b-cell lymphoma myc- and bcl2-positive chidamide zanubrutinib lenalidomide elderly patients